NSD-867 belongs to the group of cortical enhancers, i.e. drugs with a relatively stronger effect in the cerebral cortex and in the deeper brain structures compared with dopaminergic stabilisers. This profile shows indications of being ideal as a drug for the treatment of cognitive disorders such as ADHD. Compared with existing medications for the treatment of ADHD and other kinds of attention disorders, cortical enhancers are expected to have a much better safety profile, with a reduced risk of developing psychoses, sleep disorders and obesity. NSD-867 has been selected as the first development candidate from the programme, and GSK holds an option for both this candidate and NSD-847.